Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert Eugene Watson is Director at Cel Sci. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jul 29, 2025, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
1 buy, median −7.9 pts vs S&P 500, beat it 0 of 1 time.
Average −7.9 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Jul 29, 2025 to Jul 29, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.8 pts (median, against the S&P 500).
Cel SciCVM
Jul 25, 2025Bought~$20Kdisclosed Jul 29
DetailsOfficial recordAs of the latest filing on , Robert Eugene Watson reported holding 3,733 shares of Cel Sci (CVM), worth about $5.5K at the last close of $1 (Nov 19, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Cel Sci CVM | 3,733 | 3,733 direct | $1 | $5.5K | Jul 25, 2025 |
Is this Robert Eugene Watson’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Robert Eugene Watson bought shares on the open market in 2020, 2021, 2024 and 2025.
Robert Eugene Watson reported 5 open-market purchases and 0 sales since 2020; purchases in 4 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $20K1×1 trade | — |
| 2024 | $28K1×1 trade | — |
| 2021 | $10K1×1 trade | — |
| 2020 | $19K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Jul 25, 2025, Robert Eugene Watson reported holding 3,733 shares of Cel Sci (CVM). At the last close of $1 on Nov 19, 2026, that is about $5.5K. This is the stake disclosed in filings, not a net worth.
No public filing gives Robert Eugene Watson's net worth. What SEC Form 4 shows is the stock stake: 3,733 shares of Cel Sci (CVM), about $5.5K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Robert Eugene Watson bought shares on the open market in 2020, 2021, 2024 and 2025.
In SEC filings since 2020: the latest open-market purchase is from 2025; no open-market sale is on record.
Cel Sci (CVM), from 2020 to 2025: 5 purchases and 0 sales.
Robert Eugene Watson reported 5 open-market purchases and 0 sales here, 2020 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.